Crinetics Pharmaceuticals Inc To Discuss Results From MAD Cohorts Of The Phase 1 Trial Of CRN04777 Corporate Call Transcript
Greetings, and welcome to Crinetics Pharmaceuticals conference call. (Operator Instructions). As a reminder, this conference is being recorded.
I would now like to turn this conference over to your host, Mr. Thomas Galassi with LifeSci Advisors. Thank you, sir. You may begin.
Thank you, operator, and thank you all for participating in today's conference call.
Before we start, I would like to point out that there is a slide deck that will accompany today's presentation. This slide deck can be viewed using the webcast link provided on the Investors page of the Crinetics Pharmaceuticals website. Also posted on this web page is a news release issued earlier today, announcing top line data for the multiple ascending dose portion of the Phase I study evaluating CRN04777, which is the topic of today's call.
However, before we get to discussion of the Phase I results, I'd like to remind all listening and some of the information contained in the news release and on this
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |